ReP USP - Resultado da busca

Artigo de periodico
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial (2019)
Herbst, R. S; Baas, P; Perez-gracia, J. L; Felip, E; Kim, D. -W; Han, J. -Y; Molina, J. R; Kim, J. -H; Arvis, C. Dubos; Castro Junior, Gilberto de
Fonte: Annals of oncology. Unidade: FM
Assuntos: IMUNOHISTOQUÍMICA, ANTINEOPLÁSICOS, NEOPLASIAS PULMONARES, CÉLULAS CULTIVADAS DE TUMOR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HERBST, R. S et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals of oncology, v. 30, n. 2, p. 281-289, 2019Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdy545. Acesso em: 26 out. 2025.
APA
Herbst, R. S., Baas, P., Perez-gracia, J. L., Felip, E., Kim, D. -W., Han, J. -Y., et al. (2019). Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals of oncology, 30( 2), 281-289. doi:10.1093/annonc/mdy545
NLM
Herbst RS, Baas P, Perez-gracia JL, Felip E, Kim D-W, Han J-Y, Molina JR, Kim J-H, Arvis CD, Castro Junior G de. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial [Internet]. Annals of oncology. 2019 ; 30( 2): 281-289.[citado 2025 out. 26 ] Available from: https://doi.org/10.1093/annonc/mdy545
Vancouver
Herbst RS, Baas P, Perez-gracia JL, Felip E, Kim D-W, Han J-Y, Molina JR, Kim J-H, Arvis CD, Castro Junior G de. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial [Internet]. Annals of oncology. 2019 ; 30( 2): 281-289.[citado 2025 out. 26 ] Available from: https://doi.org/10.1093/annonc/mdy545
Artigo de periodico
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) (2019)
Bachelot, T; Ciruelos, E; Schneeweiss, A; Puglisi, F; Peretz-Yablonski, T; Bondarenko, I; Paluch-shimon, S; Wardley, A; Merot, J. -L; Hegg, Roberto
Fonte: Annals of oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, METÁSTASE NEOPLÁSICA, RESULTADO DE TRATAMENTO, QUIMIOTERAPIA COMBINADA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BACHELOT, T et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, v. 30, n. 5, p. 766-773, 2019Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdz061. Acesso em: 26 out. 2025.
APA
Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., et al. (2019). Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, 30( 5), 766-773. doi:10.1093/annonc/mdz061
NLM
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2025 out. 26 ] Available from: https://doi.org/10.1093/annonc/mdz061
Vancouver
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2025 out. 26 ] Available from: https://doi.org/10.1093/annonc/mdz061
Trabalho de evento-resumo periodico
Young-age ic tumor burden and cardiovascular comorbidities linked to carcinoid heart disease (2017)
Fujiki, F. K; Silva, A. C. B; Zambrano, E. M; Fonseca, L. G; Braghiroli, M. I; Sabbaga, J; Hoff, Paulo Marcelo Gehm
Fonte: Annals of oncology. Nome do evento: 42nd European-Society-for-Medical-Oncology Congress (ESMO). Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS, IMUNOHISTOQUÍMICA, SINAIS E SINTOMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FUJIKI, F. K et al. Young-age ic tumor burden and cardiovascular comorbidities linked to carcinoid heart disease. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://observatorio.fm.usp.br/handle/OPI/25154. Acesso em: 26 out. 2025. , 2017
APA
Fujiki, F. K., Silva, A. C. B., Zambrano, E. M., Fonseca, L. G., Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. G. (2017). Young-age ic tumor burden and cardiovascular comorbidities linked to carcinoid heart disease. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://observatorio.fm.usp.br/handle/OPI/25154
NLM
Fujiki FK, Silva ACB, Zambrano EM, Fonseca LG, Braghiroli MI, Sabbaga J, Hoff PMG. Young-age ic tumor burden and cardiovascular comorbidities linked to carcinoid heart disease [Internet]. Annals of oncology. 2017 ; 28[citado 2025 out. 26 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25154
Vancouver
Fujiki FK, Silva ACB, Zambrano EM, Fonseca LG, Braghiroli MI, Sabbaga J, Hoff PMG. Young-age ic tumor burden and cardiovascular comorbidities linked to carcinoid heart disease [Internet]. Annals of oncology. 2017 ; 28[citado 2025 out. 26 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25154
Trabalho de evento-resumo periodico
Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 (2017)
Bachelot, T; Royce, M; Villanueva, C; Cruz, F. Melo; Hegg, Roberto; Falkson, C; Jeong, J; Srimuninnimit, V; Arce, C. H; Ridolfi, A
Fonte: Annals of oncology. Nome do evento: 42nd European-Society-for-Medical-Oncology Congress (ESMO). Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, PROGNÓSTICO, SOBREVIVÊNCIA LIVRE DE DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BACHELOT, T et al. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://observatorio.fm.usp.br/handle/OPI/25260. Acesso em: 26 out. 2025. , 2017
APA
Bachelot, T., Royce, M., Villanueva, C., Cruz, F. M., Hegg, R., Falkson, C., et al. (2017). Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://observatorio.fm.usp.br/handle/OPI/25260
NLM
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [Internet]. Annals of oncology. 2017 ; 28[citado 2025 out. 26 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25260
Vancouver
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [Internet]. Annals of oncology. 2017 ; 28[citado 2025 out. 26 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25260
Artigo de periodico
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (vol 28, pg 2517, 2017) (2017)
Quaglino, P; Maule, M; Prince, H. M; Porcu, P; Horwitz, S; Duvic, M; Talpur, R; Vermeer, M; Bagot, M; Sanches Junior, Jose Antonio
Fonte: Annals of oncology. Unidade: FM
Assuntos: MICOSES, SEGUIMENTOS, ESTUDOS MULTICÊNTRICOS, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
QUAGLINO, P et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (vol 28, pg 2517, 2017). Annals of oncology, v. 30, n. 3, p. 494-494, 2017Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdy207. Acesso em: 26 out. 2025.
APA
Quaglino, P., Maule, M., Prince, H. M., Porcu, P., Horwitz, S., Duvic, M., et al. (2017). Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (vol 28, pg 2517, 2017). Annals of oncology, 30( 3), 494-494. doi:10.1093/annonc/mdy207
NLM
Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Sanches Junior JA. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (vol 28, pg 2517, 2017) [Internet]. Annals of oncology. 2017 ; 30( 3): 494-494.[citado 2025 out. 26 ] Available from: https://doi.org/10.1093/annonc/mdy207
Vancouver
Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Sanches Junior JA. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (vol 28, pg 2517, 2017) [Internet]. Annals of oncology. 2017 ; 30( 3): 494-494.[citado 2025 out. 26 ] Available from: https://doi.org/10.1093/annonc/mdy207

Unidades USP

ReP

Filtros

Autores

Assuntos